Short answer: Foundayo is a new once-daily weight-loss pill that works through the same GLP-1 pathway as Wegovy and Ozempic, but it's built from an entirely different type of molecule — one that doesn't require fasting or special timing to work. In labeled Trial 1 results at the commercial maximum dose, it produced meaningful weight loss, though somewhat less than the strongest injectable options.
If you've come across the name Foundayo and aren't sure how it fits alongside Wegovy, Zepbound, or the other GLP-1 medications you've heard of, here's what it actually is, how it's different at a chemical level, and what the trial data shows.
Jump to section
What Foundayo Actually Is
Foundayo is the brand name for orforglipron, a medication developed by Eli Lilly.[1] Like Wegovy and Ozempic, it activates the GLP-1 receptor — the same hormone pathway responsible for reducing appetite, slowing digestion, and helping regulate blood sugar. Where it differs is in what kind of molecule it is.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are both peptides — essentially short chains of amino acids engineered to mimic natural gut hormones. Orforglipron is not a peptide at all. It's a small-molecule drug, chemically closer to a conventional pill medication like ibuprofen or a statin than to an injectable peptide hormone.[3]
Why That Distinction Actually Matters
Peptides are fragile. They get broken down by stomach acid and digestive enzymes almost immediately, which is why semaglutide was only available as an injection for years, and why the oral version that eventually launched (the Wegovy pill) needs a special absorption-enhancing ingredient and strict fasting rules to work at all.[5]
Small molecules like orforglipron don't have this problem. They're naturally more resistant to digestion and can be absorbed through the intestinal lining without any special workaround. That's the direct reason Foundayo can be taken once daily with no fasting, no water restrictions, and no waiting period before eating — a real practical difference from oral semaglutide, not just a marketing distinction.[3]
FDA Approval
Foundayo was approved by the FDA on April 1, 2026 under the agency's National Priority Voucher program — the first new molecular entity approved under that pathway.[1] Its approved use is for reduction and long-term maintenance of excess body weight in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity.[2]
As of this initial approval, Foundayo is positioned specifically as a weight-management medication. A type 2 diabetes indication is being studied separately and is not yet part of the current label — so if you're looking at Foundayo for diabetes rather than weight management, that's not what it's currently approved for.[3]
The medication is taken once daily as an oral tablet. Approved tablet strengths are 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. Labeling starts at 0.8 mg and steps up (2.5 → 5.5, then up to 9 / 14.5 / 17.2 mg) with at least 30 days at each step; the maximum recommended dose is 17.2 mg once daily.[3]
What the Trials Found
Foundayo's approval was based on two 72-week placebo-controlled trials in adults with obesity or overweight. In labeled Trial 1 results at the commercial maximum dose of 17.2 mg once daily, mean body-weight change was about −11.1% versus −2.1% with placebo at 72 weeks.[3][4] Across approved doses in the labeling, results were meaningfully better than placebo, alongside improvements in cardiometabolic markers reported in the trials.
How That Compares to Other GLP-1 Options
Lined up against the major trials for other GLP-1 medications:
| Medication | Trial | Duration | Avg Weight Loss |
|---|---|---|---|
| Foundayo (orforglipron), 17.2 mg | Trial 1 (label) | 72 weeks | −11.1% vs −2.1% placebo |
| Oral semaglutide 25 mg (Wegovy pill) | OASIS-4 | 64 weeks | ~13.6% |
| Injectable semaglutide 2.4 mg (Wegovy) | STEP-1 | 68 weeks | ~14.9% |
| Injectable tirzepatide, up to 15 mg (Zepbound) | SURMOUNT-1 | 72 weeks | Up to 20.9% |
Foundayo's labeled Trial 1 result at 17.2 mg lands at the more modest end of the current GLP-1 landscape — meaningfully better than placebo, but behind both injectable semaglutide (~14.9% in STEP-1) and high-dose oral Wegovy trial results, and further behind tirzepatide (up to 20.9% in SURMOUNT-1), which remains the strongest performer across trials due to its dual-receptor mechanism.[3][6][7]
Cross-trial comparisons between oral semaglutide and Foundayo should be read cautiously — different studies, populations, and analysis methods make exact percentage-point gaps hard to pin down without a dedicated head-to-head in the weight-management setting. Separately, some diabetes-dose comparisons of orforglipron versus lower-dose oral semaglutide have been reported in other programs; those results don't automatically translate to the high-dose oral Wegovy weight-management setting, so the practical takeaway still depends on which dose and indication you're comparing.
Side Effects
Foundayo's side effect profile follows the same pattern as every other GLP-1 medication: nausea, constipation, diarrhea, vomiting, and abdominal discomfort are among the most commonly reported effects, generally mild to moderate in severity. These gastrointestinal symptoms were also a leading reason participants discontinued treatment in trials — consistent with what's seen across the entire GLP-1 drug class, regardless of whether the medication is a pill or an injection.[3] Like other GLP-1 receptor agonists in this class, Foundayo carries a boxed warning related to thyroid C-cell tumors (medullary thyroid carcinoma) and is contraindicated in patients with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).[3]
Foundayo vs. Oral Semaglutide: The Practical Difference
Since both are pills, this is probably the most relevant comparison for anyone specifically trying to avoid injections.
Oral semaglutide (Wegovy pill, Rybelsus) requires a co-formulated absorption enhancer to survive digestion, and that comes with real constraints: taken on an empty stomach, with only a small amount of plain water, and a mandatory wait before eating or taking other medications.[5]
Foundayohas none of these restrictions. It's taken once daily without regard to meals or timing.[3]
The tradeoff is in the numbers: oral semaglutide's high-dose weight-management trial results were somewhat stronger than Foundayo's labeled Trial 1 figure at 17.2 mg. So the practical choice comes down to a real tradeoff — Foundayo offers meaningfully more convenience day-to-day, while oral semaglutide has shown somewhat stronger average results at its highest studied weight-management dose.[3][5]
What's Being Studied Next
Eli Lilly is continuing to study orforglipron for additional uses, including type 2 diabetes — early trial data has shown improvements in blood sugar control alongside weight loss. There's also ongoing research into whether people who've already lost weight on an injectable medication like tirzepatide can maintain that weight loss after switching to Foundayo, which would be a meaningful option for someone who wants to eventually move off injections without losing progress. None of this pipeline work has resulted in expanded FDA approvals yet — it's worth watching, not yet available.
Sources
- FDA Approves First New Molecular Entity Under National Priority Voucher Program — U.S. Food and Drug Administration fda.gov
- FOUNDAYO (orforglipron) — Approval Letter — U.S. Food and Drug Administration accessdata.fda.gov
- FOUNDAYO (orforglipron) — Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- FOUNDAYO (orforglipron) — DailyMed — NLM DailyMed dailymed.nlm.nih.gov
- WEGOVY (semaglutide) tablets — Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine nejm.org
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine nejm.org
Frequently Asked Questions
Q: Is Foundayo the same thing as Ozempic or Wegovy?
No. All three work through the GLP-1 receptor, but Foundayo (orforglipron) is a completely different type of molecule — a small molecule rather than a peptide — which is why it doesn't need the injection or the fasting rules that come with semaglutide-based medications.
Q: Does Foundayo require fasting like the Wegovy pill does?
No — this is one of its main advantages. Foundayo can be taken once daily without food or water restrictions, unlike oral semaglutide.
Q: Is Foundayo as effective as Wegovy or Zepbound?
Not quite, based on labeled and major trial data. Foundayo's Trial 1 result at the commercial max dose of 17.2 mg was about −11.1% average weight loss vs −2.1% placebo at 72 weeks — somewhat lower than injectable semaglutide (~14.9% in STEP-1) and notably lower than injectable tirzepatide (up to 20.9% in SURMOUNT-1). It's still a clinically meaningful result, just not the strongest option currently available.
Q: Can Foundayo be used for type 2 diabetes?
Not yet — its current FDA approval is specifically for weight management. Diabetes-focused trials are ongoing but haven't resulted in an expanded approval as of this writing.
Q: Is Foundayo available as an injection too?
No, Foundayo is only available as an oral tablet. There's no injectable version of orforglipron.
See also: Foundayo vs. Semaglutide vs. Tirzepatide · Oral vs. Injectable GLP-1 · What Is a GLP-1 Medication? · Shop oral GLP-1 prices